Zenosense, Inc.: MIDS Medical Expands Technical Team
October 02 2018 - 7:42AM
InvestorsHub NewsWire
Valencia, Spain -- October 02, 2018 -- InvestorsHub NewsWire --
Zenosense, Inc. (OTCQB: ZENO, "Zenosense", the "Company"), a
healthcare technology company focused on the development and
commercialization of the MIDS Cardiac™ hand-held technology for the
early detection of heart attack at the Point of Care, is pleased to
announce that its MIDS Medical Ltd. joint venture (“JV", “MML") has
expanded its technical team to support the next phase of
development of MIDS Cardiac.
Following its recent funding agreement MML has arranged the
services of three key contractors for its next phase of MIDS
development. These contracting arrangements are designed to
efficiently obtain services as and when required by MML.
The Magnetism Group at the University of Liverpool led by Dr
Liam O'Brien, lecturer at the University of Liverpool and a member
of the Condensed Matter Physics group and Materials Innovation
Factory, will assist MML in the calibration and development of its
medical diagnostic technologies. Dr O’Brien’s experience includes
spatially-resolved Kerr effect microscopy, magnetic nanostructures,
thin film magnetic materials, and spintronic devices and will be
used to assist MML with microfluidic design in conjunction with its
established technical design consultants. This is expected to
include the computer simulation of microfluidic and magnetic bias
field instigated flow of fluids and assay beads within the MIDS
microfluidic strip prior to manufacture, and verification of built
specification once manufactured.
Magnetism Group leader Dr O’Brien commented: “MIDS next
generation technology offers exciting prospects in point-of-care
diagnostics. We look forward to working with their team. This
is an ideal opportunity to use our expertise in nanoscale magnetic
materials characterisation to assist Dr Djennati and his team in
the development of MML medical devices.”
MML has also arranged the services of two independent
electronics engineers with a combined and complementary experience
of over fifty years in the electronic disciplines demanded by the
MIDS project. This includes embedded digital and analogue hardware
and software design, multilayer PC design, immunoassay and magnetic
particle experience, control systems and data acquisition.
About Zenosense, Inc.
Zenosense Inc., through a joint-venture ownership in MIDS
Medical Ltd., is primarily focused on the development of a
cost-effective, hand-held Point of Care rapid cardiac diagnostic
device, MIDS Cardiac. MIDS Medical applies patent-protected
magnetic nanoparticle detection technology and a development team
with world-class technical expertise. The MIDS Cardiac device and
test strip is being designed to support a variety of rapid high
sensitivity cardiac biomarker tests, with a focus on troponin I and
T, to identify or discount Acute Myocardial Infarction with
accuracy equal or superior to high sensitivity assays performed on
laboratory analyzers. To find out more about Zenosense,
visit www.zenosense.com
Forward-Looking Statements
Statements in this news release that are not statements of
historical fact are forward-looking statements, which are subject
to certain risks and uncertainties. Forward-looking
statements can often be identified by words such as "expects,”
"intends,” "plans,” "may,” "could,” "should,” "anticipates,”
"likely,” "believes" and words of similar import.
Forward-looking statements are based on current facts and analyses
and other information that are based on forecasts of future
results, estimates of amounts not yet determined and assumptions of
management. Actual results may differ materially from those
expressed or implied by forward-looking statements due to a variety
of factors that may or may not be foreseeable or within the
reasonable control of the Company. Readers are cautioned not
to place undue reliance on such forward-looking statements.
Additional information on risks and other factors that may affect
the business and financial results of the Company can be found in
filings of the Company with the U.S. Securities and Exchange
Commission, including without limitation the section entitled “Risk
Factors” in the Company’s Annual Report on Form 10-K for the year
ended December 31, 2017 filed on filed on April 17, 2018, and in
Company reports filed subsequently thereto. Except as
otherwise required by law, the Company disclaims any obligations or
undertaking to publicly release any updates or revisions to any
forward-looking statement contained in this news release to reflect
any change in the Company’s expectations with regard thereto or any
change in events, conditions or circumstances on which any such
statement is based. Respective statements concerning the
development of both MIDS Cardiac™ and other devices under
development have been made based on information obtained from MIDS
Medical Ltd. and Zenon Biosystem, which the Company believes to be
accurate, but have not been independently verified.
Contact:
Zenosense, Inc.
www.zenosense.com
Tel: +34 960 454 202
ir@zenosense.net
Zenosense Inc NV (CE) (USOTC:ZENO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zenosense Inc NV (CE) (USOTC:ZENO)
Historical Stock Chart
From Apr 2023 to Apr 2024